Prevalence of factor v Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: Geographical and age distribution

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 7, 2009, Pages 503-510

  Mazoyer, Elisabeth ^a,e   Ripoll, Laurent ^a   Gueguen, René ^b   Tiret, Laurence ^c   Collet, Jean Philippe ^c   Bal Dit Sollier, Claire ^a   Roussi, Jacqueline ^d   Drouet, Ludovic ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

^b Ctr Tech d'Appui Form C   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d RAYMOND POINCARÉ HOSPITAL   (France)

^e AVICENNE HOSPITAL   (France)

Author keywords

Factor V Leiden; Genetic and environmental factors; Geographic distribution; Prevalence; Prothrombin G20210A mutation; Prothrombin plasma level

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; D DIMER; PROTHROMBIN; BLOOD CLOTTING FACTOR 5; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD GROUP; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FIBRIN CLOT; FRANCE; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; HEREDITY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL CONTRACEPTION; PREVALENCE; PRIORITY JOURNAL; VEIN THROMBOSIS; YOUNG MODULUS; ADOLESCENT; CLINICAL TRIAL; EPIDEMIOLOGY; GENETICS; MIDDLE AGED; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; POINT MUTATION; POPULATION GROUP; RISK FACTOR; TOPOGRAPHY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FACTOR V; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FRANCE; HUMANS; MALE; MIDDLE AGED; POINT MUTATION; POPULATION GROUPS; PREVALENCE; PROTHROMBIN; RISK FACTORS; TOPOGRAPHY, MEDICAL; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 70349835752     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832f5d7a     Document Type: Article

References (35)

1. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346:1133-1134.
2. Rees DC. The population genetics of factor V Leiden (Arg506Gln). Br J Haematol 1996; 95:579-586.
3. Pepe G, Rickards O, Vanegas OC, Brunelli T, Gori AM, Giusti B, et al. Prevalence of Factor V Leiden mutation in non-European population. Thromb Haemost 1997; 77:329-331.
4. Lucotte G, Mercier G. Population genetics of factor V Leiden in Europe. Blood Cells Mol Dis 2001; 27:362-367.
5. Jun ZJ, Ping T, Lei Y, Li L, Ming SY, Jing W. Prevalence of factor V Leiden and prothrombin G20210 mutations in Chinese patients with deep venous thrombosis and pulmonary embolism. Clin Lab Haematol 2006; 28:111-116.
6. Angchaisuksiri P, Pingsuthiwong S, Aryuchai K, Busabaratana M, Sura T, Atichartakan V, et al. Prevalence of the G1691A mutation in the factor V gene (factor V Leiden) and the G20210A prothrombin gene mutation in the Thai population. Am J Hematol 2000; 65:119-122.
7. Irani-Hakime N, Tamim H, Kreidy R, Almawi W. The prevalence of factor V R506Q mutation Leiden among apparently healthy Lebanese. Am J Hematol 2000; 65:45-49.
8. Bouaziz-Borgi L, Almavwi WY, Mtiraoui N, Nsiri B, Keleshian SH, Kreidy R, et al. Distinct association of Factor V-Leiden and prothrombin G20210A mutations with deep venous thrombosis in Tunisian and Lebanon. Am J Hematol 2006; 81:641-643.
9. Almawi WY, Keleshian SH, Borgi L, Fawaz NA, Abboud N, Mtiraoui N, et al. Varied prevalence of Factor V G1691A (Leiden) and Prothrombin G20210 single nucleotide polymorphism among Arabs. J Thromb Thrombol 2005; 20:163-168.
10. Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Siscovic DS, et al. Geographic distribution of the 20210G to A prothrombin variant. Thromb Haemost 1998; 79:706-708.
11. Hessner MJ, Dinauer DM, Kwiatowski R, Neri B, Raife TJ. Age-dependent prevalence of vascular disease-associated polymorphisms among 2689 volunteer blood donors. Clin Chem 2001; 47:1879-1884.
12. Heijmans BT, Westendorp RG, Knook DL, Kluft C, Slaboom PE. The risk of mortality and of Factor V Leiden in a population-based cohort. Thromb Haemost 1998; 80:607-609.
13. Morelli VM, De Visser MCH, Vos HL, Bertina RM, Rosendaal R. ABO blood group genotypes and the risk of venous thrombosis effect of factor V Leiden. J Thromb Haemost 2005; 3:183-185.
14. Procare-GEHT Group. ABO blood group but not haemostasis genetic polymorphisms significantly influence thrombotic risk: a study of 180 homozygotes for factor V Leiden mutation. Br J Haematol 2006; 135:697-702.
15. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previous unrecognised mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90:1004-1008.
16. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
17. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-unrelated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703.
18. Gehring NH, Frede U, Neu-Yilik G, Hundsdoerfer P, Vetter B, Hentze MW, Kulozik AE. Increased efficiency of mRNA 3'end formation: a new genetic mechanism contribution to hereditary thrombophilia. Nat Genet 2001; 28:389-392.
19. Brugge JM, Tans G, Rosing J, Castoldi E. Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels. Thromb Haemost 2006; 95:236-242.
20. Ripoll L, Paulin D, Thomas S, Drouet LO. Multiplex PCR-mediated sitedirected mutagenesis for one-step determination of factor V Leiden and G20210A transition of the prothrombin gene. Thromb Haemost 1997; 78:960-961.
21. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extraction DNA from human nucleated cells. Nucleic Acid Res 1988; 16:1215.
22. Carr ME, Zeckert SL. Measurement of platelet mediated force development during plasma clot formation. Am J Med Sci 1991; 302:13-18.
23. Greilich PE, Carr ME, Zekert SL, Dent RM. Quantitative assessment of platelet function and clot structure in patients with severe coronary artery disease. Am J Med Sci 1994; 307:15-20.
24. Lucotte G, Mercier G. Frequency of Factor V Leiden (Arg506Gln) in France. Br J Haematol 1997; 99:237-241.
25. Bauduer F, Ducout L, Freyburger G. Assessment of the 20210 G to A prothrombin variant in a sample of patients from the French Basque country with various thrombophilic conditions. Ann Hematol 2003; 82:353-356.
26. Bauduer F, Zivelin A, Ducout L, Shpringer E, Seligsohn U. The prevalence of factor V G1691A but not of prothrombin G20210A and methylenetetrahydrofolate reductase C677T is remarkably low in French Basques. J Thromb Haemost 2004; 2:361-362.
27. Delahouse B, Gilbert M, Nicham F, Thirion C, Giraudeau B, Gruel Y. Comparative evaluation of five different methods for the measurement of plasma factor II levels in carriers of the 20210A prothrombin variant. Blood Coagul Fibrinolysis 2002; 13:465-470.
28. Von Ahsen N, Lewczuk P, Schutz E, Oellerich M, Ehrenreich H. Prothrombin activity and concentration in healthy subjects with and without the prothrombin G20210A mutation. Thromb Res 2000; 99:549-556.
29. Ceelie H, Bertina RM, van Hylckama Vlieg A, Rosendaal FR, Vos HL. Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels. Thromb Haemost 2001; 85:1066-1070.
30. Moyer MP, Tracy RP, Tracy PB, Van't Veer C, Sparks CE, Mann KG. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arterioscler Thromb Vasc Biol 1998; 18:458-465.
31. Hoffman CJ, Lawson WE, Miller RH, Hultin MB. Correlation of vitamin K dependent clotting factors with cholesterol and triglycerides in healthy young adults. Arterioscler Thromb 1994; 14:1737-1740.
32. Hoffman CJ, Miller RH, Hultin MB. Correlation of factor VII activity and antigen with cholesterol and triglycerides in healthy young adults. Arterioscler Thromb 1992; 12:267-270.
33. Wolberg AS, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood 2003; 101:3008-3013.
34. Zivelin A, Mor-Cohen R, Kovalsky V, Kombrot N, Connard J, Peyvandi F, et al. Prothrombin 20210G>A is an ancestral prothromotic mutation that occurred in whites approximately 24000 years ago. Blood 2006; 107:4666-4668.
35. Mari D, Mannucci PM, Duca F, Bertolini S, Franceschi C. Mutant factor V (Arg506Gln) in healthy centenarians. Lancet 1996; 347:1044.